nemolizumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
monoclonal antibodies (humanized origin); lymphocyte 5689 1476039-58-3

Description:

MoleculeDescription

Molfile

Synonyms:

  • nemolizumab
  • nemolizumab (genetical recombination)
  • CIM331
  • mitchga
Nemolizumab is a subcutaneously administered humanized anti-interleukin-31 (IL-31) receptor A (IL-31RA) monoclonal antibody to treat skin diseases, including atopic dermatitis, AD associated pruritus, prurigo nodularis, chronic kidney disease associated pruritus and systemic sclerosis.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
March 28, 2022 PMDA Maruho Co., Ltd.

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 139.68 55.51 72 636 541453 90086286
Dermatitis atopic 128.90 55.51 31 677 23441 90604298
Neurodermatitis 108.30 55.51 19 689 3019 90624720
Eczema 86.78 55.51 27 681 52843 90574896
Rash 57.58 55.51 48 660 796052 89831687

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Pruritus 96.69 78.54 38 236 188733 42432328
Dermatitis atopic 85.74 78.54 19 255 12385 42608676

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis atopic 182.58 62.02 41 743 25500 110563015
Pruritus 156.04 62.02 77 707 581483 110007032
Neurodermatitis 124.58 62.02 21 763 2911 110585604
Eczema 93.16 62.02 30 754 72263 110516252

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC D11AH12 DERMATOLOGICALS
OTHER DERMATOLOGICAL PREPARATIONS
OTHER DERMATOLOGICAL PREPARATIONS
Agents for dermatitis, excluding corticosteroids
MeSH PA D003879 Dermatologic Agents
FDA EPC N0000194121 Interleukin-31 Receptor alpha Antagonist
FDA MoA N0000194122 Interleukin-31 Receptor alpha Antagonists
CHEBI has role CHEBI:50177 dermatologic drug

Related Drugs by ATC class:

D11AH Agents for dermatitis, excluding corticosteroids 11 drugs
abrocitinibalitretinoincrisaborolecromoglicic aciddelgocitinibdupilumablebrikizumabpimecrolimusruxolitinibtacrolimustralokinumab

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Pruritus associated with atopic dermatitis indication 24079001 DOID:3310




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Interleukin-31 receptor subunit alpha Cytokine INHIBITOR Kd 9.43 SCIENTIFIC LITERATURE SCIENTIFIC LITERATURE

External reference:

IDSource
CHEBI:757240 CHEBI
CHEMBL4297794 ChEMBL_ID
C000612881 MESH_SUPPLEMENTAL_RECORD_UI
8720 IUPHAR_LIGAND_ID
DB15252 DRUGBANK_ID
933506281000036107 SNOMEDCT_US
4043334 VANDF
C4505530 UMLSCUI
10064 INN_ID
D11080 KEGG_DRUG
43049 MMSL
d10210 MMSL
GN465U8B72 UNII
2691310 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
NEMLUVIO HUMAN PRESCRIPTION DRUG LABEL 1 0299-6220 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 30 mg SUBCUTANEOUS BLA 28 sections